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Transient inhibition of angiotensinogen production in transgenic
mice bearing an antisense angiotensinogen gene
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Division of Hypertension, Lausanne University Medical Schoo4 Lausanne, Switzerland
Transient inhibition of angiotensinogen production in transgenic mice
bearing an antisense angiotensinogen gene. Angiotensinogen is the pre-
cursor of the biologically active hormone angiotensin II. Enzyme kinetic
parameters suggest that concentrations of plasma angiotensinogen are
rate limiting in the renin reaction. It is therefore assumed that a decrease
in angiotensinogen synthesis in vivo would result in a decrease in
angiotensin H plasma levels and then of blood pressure. To test this
hypothesis, we generated a transgenic mouse line that carries an inducible
antisense angiotensinogen gene. Transient inhibition of angiotensinogen
synthesis could be demonstrated in these transgenic animals. However, the
amounts of liver angiotensinogen message and plasma angiotensinogen
concentrations were rapidly back to levels observed in control animals.
The renin-angiotensin system plays a pivotal role in the main-
tenance of blood pressure, fluid and sodium homeostasis [1]. The
glycoprotein angiotensinogen is cleaved by the renin enzyme to
generate the inactive angiotensin I peptide. Further cleavage of
angiotensin I by the angiotensin converting enzyme (ACE) pro-
duces the biologically active hormone, angiotensin II. Although
angiotensinogen mRNA has been detected in many tissues,
including the brain and the kidneys, the protein is predominantly
synthetized in hepatocytes and the liver represents the major
source of plasma angiotensinogen [2, 3]. Given that the plasma
concentrations of angiotensinogen in rodents are close to the Km
value of the renin reaction, it is expected that angiotensinogen is
rate limiting in the production of angiotensin I [4]. Therefore,
small variations in the angiotensinogen plasma levels should
change the activity of the renin-angiotensin system and as a
consequence blood pressure values. Indeed, it has been shown
that acute infusion of pure angiotensinogen results in a transient
increase in blood pressure, whereas blockade of angiotensinogen
via administration of anti-angiotensinogen antibodies can cause a
significant fall in blood pressure [5—7].
The efficacy of ACE inhibitors in the treatment of hypertensive
patients is widely recognized, suggesting that angiotensin II is
crucial in the pathogenesis of hypertension and in the develop-
ment of left ventricular hypertrophy [8]. However, because ACE
inhibitors are not completely selective, there is still a controversy
whether this is a specific angiotensin-dependent mechanism.
Furthermore, since ACE inhibitors do not result in complete
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blockade of the renin-angiotensin system, the safety of a more or
less permanently inhibited renin.angiotensin system has not been
established. More recently, renin inhibitors have also been tested
as a means to specifically block the renin-angiotensin system [9,
10]. Although promising, the short-term effect of these drugs
prevents their use in chronic treatments [11]. In this context,
angiotensinogen might represent an attractive target to inhibit
angiotensin I, and then angiotensin II, production. We therefore
evaluated the possibility to specifically block the renin-angiotensin
system through a reduction of angiotensinogen synthesis by
antisense inhibition.
Regulation of gene expression by transcription of an antisense
RNA complementary to an endogenous message has first been
described as a naturally occurring repressor mechanism [12].
Expression is inhibited through hybridization of the antisense
molecule to the coding sequence by simple base pairing. It has
been suggested that the binding could make the mRNA more
sensitive to degradation but it is also possible that simple steric
blocking could interfere with the subsequent maturation and
translation of the RNA transcript. These observations have been
fully exploited in the antisense oligonucleotide approach to inhibit
protein synthesis [13]. In parallel, the production of antisense
RNA's in transfected cells [14, 15] or in transgenic mice [16—19]
has been used successfully to prevent the expression of specific
genes in vivo. In this case, an antisense gene is constructed by the
adjunction of a particular promoter to a fragment of DNA placed
in the opposite direction so that the transcribed antisense mole-
cule will be complementary to the target messenger RNA.
To test the possibility of chronically blocking the renin-angio-
tensin system by reducing plasma angiotensinogen concentrations,
a transgenic mouse line was generated, harboring an antisense
angiotensinogen gene under control of a liver-specific promoter.
The promoter of the phosphoenolpyruvate carboxykinase (pepck)
gene, a key enzyme involved in gluconeogenesis, was chosen for
several reasons. First, although the pepck gene is expressed in a
variety of tissues, the fragment of the promoter that was used in
our study contained primarily the cis-acting sequences required
for high liver expression [20]. In addition, the level of activity of
the pepck promoter in animals is responsive to diet through a
change of the insulin-to-glucagon ratio [21, 22]. More precisely, a
diet high in protein and devoid of carbohydrate increases the
pepck promoter activity, whereas a marked decrease is observed
when the animals are fed a diet high in carbohydrates and low in
protein. Finally, the levels of transcription of the pepck gene are
low in the liver of fetal animals but increase immediately after
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Fig. 1. Representation of the antisense angiotensinogen transgene and analysis of transgenic mouse genomic DNA. A. Schematic representation of the 4 Kb
Aat II (A)-Xho I (X) antisense angiotensinogen transgene composed of a 0.9 Kb Sac I (S) fragment of the pepck promoter coupled to the 1.9 Kb
angiotensinogen cDNA inserted in reverse position into the Sal I (Sa) of the vector. The IVS2 intron sequences from the rabbit 13-globin gene are also
present. Barn HI (B) sites, which are relevant for Southern analysis, are indicated. Position of the two probes used for either Southern analysis (hatched
box) or dot blotting (black box) are shown underneath. Arrows indicate the positions of the primers used for the RT-PCR detection of transgene
expression. B. Southern analysis of genomic DNA from either a normal (a) or a transgenic (b) mouse. Liver genomic DNA was digested with Barn HI,
separated on a 0.7% agarose gel, transferred on nitrocellulose and hybridized with the 0.3 Kb Aat Il-Sac I fragment described above, C. Dot blot analysis
of the F2 progeny. Denatured tail DNA was transferred on nitrocellulose and hybridized sequentially with the 0.9 Kb Sac I fragment of the pepck
promoter (a) and a control probe recognizing the renin-1 gene (b).
birth [22]. Therefore, this promoter combines tissue specificity
and inductibility and, because of its low activity before birth,
minimizes the chance of lethal transgene expression during the
fetal life. The pepck promoter was then coupled to an angio-
tensinogen cDNA in reverse position.
The present report describes the effects of the expression of an
antisense angiotensinogen transgene on the endogenous levels of
angiotensinogen mRNA and protein. Although a significant re-
duction of angiotensinogen mRNA accumulation and protein
synthesis could be demonstrated in transgenic animals, the inhi-
bition was only transient. In adult transgenic mice, the amounts of
message and protein were even higher than those measured in
normal mice.
Methods
Plasmid construction
The plasmid p6ROSE containing the rat pepck promoter was
constructed as follows. The fragment of the pepck promoter,
composed of 660 bp of regulatory sequences of the pepck gene
with 235 bp of an enhancer element that confers preferential liver
expression, was obtained after Hae II/Bgl II digestion of the
pPL9DP23 plasmid (a gift of Dr. Roger Chalkley, Vanderbilt
University, Nashville, TN, USA) [20]. The pSTX556 expression
vector (provided by Dr. Sandro Ruskoni, Institute of Biochemis-
try, Fribourg, Switzerland) [23], in which the CMV promoter and
the rat growth hormone cDNA were removed by Sac I digestion,
provided the backbone sequences plus the rabbit 3-g1obin IVS2
and polyadenylation site. The pepck promoter fragment was then
ligated to the pSTX556 sequences after Sac I linker addition to
produce the p6ROSE vector in which a unique Sal I site is present
immediately downstream to the pepck promoter. The eDNA
encoding the rat angiotensinogen was purified from an EcoRI
digest of the pGEM-Angio plasmid (a gift of Dr. Allan R. Brasier,
University of Texas, Galveston, TX, USA) [24, 25]. This fragment
was introduced into the Sal I site of p6ROSE after linker addition.
Appropriate restriction analysis identified a plasmid in which the
sequence was subcloned in reverse orientation. This plasmid was
named p6ROSE-Angio(-).
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Fig. 2. Tissue-specific expression of the antisense
angiotensinogen transgene. A. PCR detection of
the antisense angiotensinogen RNA in liver
from either a normal (a) or a transgenic mouse
(b). Total RNA was purified from liver, reverse
transcribed and subject to specific amplification
using primers spanning the angiotensinogen
eDNA and the /3-globin sequences (see
experimental procedures for exact positions of
the primers). The reverse transcription reaction
was omitted in lane c and the amplification of
transgenic mouse genomic DNA is shown in
lane d. B. Tissue-specific expression of the
antisense angiotensinogen gene. Total RNA
from a normal or a transgenic mouse, isolated
from various tissues, was amplified by PCR
using transgene-specific primers, and analysed
on agarose gel. C. Control amplification of the
different RNA's using /3-actin-specific primers.
Fertilized egg injection
DNA for microinjection was excised from the plasmid
p6ROSE-Angio(-) by Xmn I/Xho I digestion, which removes most
of the vector sequences. DNA was purified by agarose electro-
phoresis and electroelution, precipitated and resuspended at a
concentration of 3 j.tg/mI in 5 mivi Tris-HC1 pH: 7.4, 0.1 mM
EDTA. Fertilized eggs were obtained from super-
ovulated, six-week-old NMRI female mice (IFFA CREDO,
L'Arbresles, France) and kept in M2 medium until used. The male
pronuclei were injected with the DNA solution at a constant
pressure of 2 psi and viable embryos were reimplanted in the
oviduct of pseudopregnant NMRI mice.
Identification of transgenic mice
Transgenic mice were identified first by dot blot analysis of tail
DNA. At three weeks of age, 2 cm of tail were cut and digested
overnight at 55°C in 0.7 ml of Tris-HCI pH: 8.0, 100 mM EDTA,
0.5% SDS containing 500 xg/ml proteinase K. DNA was purified
by phenol/chloroform extraction and ethanol precipitated. DNA
was then denatured in 0.125 M NaOH, 0.125 X SSC and trans-
ferred on a GeneScreen Plus nitrocellulose membrane (Dupont
NEM) using a Schleicher and Schuell manifold apparatus. The
nitrocellulose filter was then UV cross linked, prehybridized six
hours and hybridized overnight at 42°C in 50% formamide, 5X
ssc, lox Denhardt, 50 m phosphate buffer pH: 7.9, 10 mM
EDTA, 1% SDS containing 100 xg/ml denatured salmon sperm
DNA. The Aat IT/Sac I fragment used as probe is described in
Figure 1 and was labeled with [a-32PjdCTP (Amersham) using a
random primed DNA labeling kit (Boehringer). The same condi-
tions were used to analyze restriction fragments of genomic liver
DNA's by Southern blotting except that the digested DNA's were
transferred, after separation in a 0.7% agarose gel, on Hybond-N
filter (Amersham) by capillary blot. The blot was hybridized with
the [a-32P}dCTP labeled pepck promoter fragment described in
Figure 1.
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Reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was purified from tissues by homogenization of a
frozen sample in 4 M guanidine isothiocyanate, 2% N-lauryl
sarcosine, 25 m sodium acetate pH: 6.0, 120 mM J3-mercapto-
ethanol. The tissue lysate was layered on top of a CsCl cushion
composed of 5.7 M CsC1 in 25 m sodium acetate. After centrif-
ugation at 100,000 g for 18 hours, the pellet was resuspended in
0.3 M sodium acetate, 0.1% SDS and ethanol precipitated. Trans-
gene and J3-actin expression was detected by RT-PCR using the
RNA GeneAmp kit (Perkin Elmer/Cetus). The conditions were
according to the manufacturer's recommendations. Oligo dT
primer was used in the reverse transcription reaction. For the
PCR amplification, two sets of primers wcre used. The transgene
specific forward primer ASF1 is homologous to the antisense
angiotensinogen sequence and the backward primer ASB4 to the
rabbit 13-globin gene. In addition, two mouse /3-actin specific
primers named BACF (forward) and BACB (backward) were
used in control experiments. The oligonucleotide sequences are as
follows. ASF1: 5'-ATC TOT GGA CTF GCT TCT GTG TGT C;
ASB4: 5'-GAT CTC AGT GGT AlT TGT GAG CCA G; BACF:
5'-TGG CAC CAC ACC TIC TAC AAT GAG; BACB: 5'-GCT
TCT CTF TGA TGT CAC GCA CG.
Ribonuclease protection assay (RPA)
Total RNA was obtained from tissues as described above. The
RPA II kit from Ambion Inc. was used to quantitate angiotensino-
0
(Ti
z
E
C
C.)
9,
0
C
a)
0C
(I)C
0
0)C
Normal diet Days on high protein diet
Fig. 4. Quantitative analysis of angiotensinogen mRNA in normal and
transgenic mice fed a high protein diet. Liver, (A) kidney (B) or brain (C)
total RNA, from either normal (ii) or transgenic mice (•) that were kept
for various times on high protein diet, was analyzed by RNase protection
assay and the levels of angiotensinogen and f3-actin mRNA were deter-
mined. The results are presented as the ratio of angiotensinogen to /3-actin
mRNA. * Significant difference compared to the normal mouse control, P
< 0.005 (SuperANOVA).
gen rnRNA in tissues. The procedure was as indicated by the
manufacturer. To synthetize the RNA probes, an angiotensinogen
template DNA was constructed by insertion of a BarnHI/Bgl II
fragment of the mouse angiotensinogen coding sequences span-
fling the first exon into the Barn HI site of the pGEM transcription
vector (Promega). A Pvu II digestion produced a linear template.
The MAXlscript kit from Ambion Inc. was used to synthetize the
angiotensinogen RNA probe from the T7 promoter in the pres-
ence of [a-32P]dUTP (Amersham). A linear mouse actin tran-
scription vector is included in the kit and the actin-specific RNA
probe was generated from the T3 promoter. The hybridization
solution contained a molar excess of the two RNA probes
together with 10 ig of the RNA sample. Protected fragments
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Fig. 3. Quantitative analysis of angiotensinogen mRNA in normal and
transgenic mice. Total RNA, isolated from liver, kidney or brain, from
either normal () or transgcnic mice (U) was analyzed by RNase
protection assay and the levels of angiotensinogen and /3-actin mRNA
were determined. The results are presented as the ratio of angiotensino-
gen to /3-actin mRNA. * Significant difference compared to normal mouse
control, P < 0.005 (SuperANOVA).
Mice
Adult, either normal or transgenic, male NMRI mice were used
at 10 to 14 weeks of age at the beginning of the experiment. The
age of newborn mice on the day of sacrifice is indicated.
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Fig. 5. Angiotensinogen concentrations in plasma
of transgenic mice. Normal (i) or transgenic() mice were kept for different times on high
protein diet and plasma angiotensinogen
concentrations were determined by indirect
radioimmunoassay following generation of
angiotensin I. Results represent the mean plus
standard error of five to seven mice per group.
* Significant difference compared to the control
group fed a normal chow, P < 0.005.
• Significant difference compared to the
normal mouse group, P < 0.005
(SuperANOVA).
ples were collected, frozen in liquid nitrogen and kept in a —70°C
freezer until used. Aliquots of plasma were diluted in 20 mM
phosphate buffer pH: 6.0 containing 30 mivi EDTA and 5 mM
phenanthroline. Samples were incubated in the presence of a
large excess of semi-purified mouse submaxillary gland renin for
two hours at 37°C. Preliminary experiments demonstrated that the
amounts of angiotensinogen present in the plasma samples are
completely cleaved in these conditions. The concentrations of
angiotensin I produced were then determined using a sensitive
radioimmunoassay [261.
Measurement of blood pressure and heart rate in conscious mice
Day after birth
Fig. 6. Angiotensinogen concentrations in plasma of newbom mice. Angio-
tensinogen concentrations were determined by indirect radioimmunoassay
in the plasma of normal (fl) or transgenic (•) newborn mice different days
after birth. Results represent the mean plus standard error of ten mice per
group. * Significant difference compared to the age-matched controls, P <
0.005 (SuperANOVA).
were separated on a 6% polyacrylamide gel. The radioactivity
associated with each band was accurately determined using an
Instant Imager detector (Packard Instruments, Meriden, CT,
USA). Results are expressed as the ratio of the angiotensinogen
to the actin mRNA.
Plasma angiotensinogen assay
Angiotensinogen concentrations were measured in plasma us-
ing an indirect method. Briefly, blood was drawn from the
retro-orbital vein (adult mice) or harvested following decapitation
(newborn mice), and EDTA was immediately added to reach a
final concentration of 10 m. After centrifugation, plasma sam-
Mice were anesthetized (3% halothane in oxygen) and a
catheter, formed by a piece of stretched PE-lO tubing, was
introduced into the femoral artery. The catheter was then passed
subcutaneously to exit at the neck. The next day, pulsatile arterial
pressure and heart rate were determined during a one hour period
by the mean of a pressure transducer connected to a physiograph
recorder.
Results
Generation of a transgenic mouse line harboring an antisense
angiotensinogen gene
In order to test the possibility of blocking the renin-angiotensin
system through an inhibition of angiotensin I production, we
decided to use the antisense approach to specifically inhibit
angiotensinogen synthesis in transgenic animals. A transgene,
composed of a fragment of the pepck gene promoter fused to a
full-length angiotensinogen eDNA placed in reverse position, was
microinjected into fertilized eggs. A schematic representation of
the transgene is depicted in Figure 1A. Transgenic mice were
identified by dot blot analysis of tail DNA using a Aat TI/Sac I
probe (Fig. 1). This report describes the characterization of the
Tsg(Angio-)4 transgenic line which results from the breeding of a
male founder bearing ten copies of the antisense transgene.
Figure lB shows a Southern blot analysis of BamHI restriction
fragments of liver genomic DNA's from normal and transgenic
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Fig. 7. Blood pressure and heart rate in
conscious mice. Normal (E) or transgenic (•)
mice were anesthesized and a catheter was
introduced in the femoral artery to the
abdominal aorta. The next day, blood pressure
(A) and heart rate (B) were recorded via a
pressure transducer during a one-hour period.
The results represent the mean plus standard
error of eight mice per group.
mice. The purified pepck promoter segment was used as probe.
The endogenous mouse pepck gene is detected as a high molec-
ular weight band (approximately 10 kb) in the genomic DNA from
either normal or transgenic mice. However, the two transgene-
specific bands of respectively 1.1 and 0.9 kb were found in the
DNA of the founder offspring only. The 0.9 kb band is likely to be
generated by the presence of a BamHI site upstream of the
transgene integration site. The transmission to progeny was
followed by dot blot hybridization of tail DNA's. Figure 1C shows
the result of a representative experiment that identifies normal,
heterozygote and homozygote mice as judged by the intensity of
the hybridization signal. The proportion of mice that segregate in
transgene-negatives (29.2%), heterozygotes (43.2%) and homozy-
gotes (27.6%), as well as the equal separation of the progeny
between male and female (52.3% vs. 47.7%), suggests an autoso-
mal Mendelian type of inheritance (total number of mice tested =
65). No obvious phenotypic differences could be observed in the
transgenic population and the development appeared normal.
Antisense gene expression
To facilitate the detection of the antisense RNA molecule,
transgene expression was followed using RT-PCR. The transgene-
specific forward primer was selected in the antisense angiotensino-
gen sequence whereas the backward primer was complementary
to the /3-globin gene. To exclude the possible amplification of
contaminating genomic DNA, the primers were selected so that
they were separated by the /3-globin intron sequences. As shown
in Figure 2A, the amplification of the expected 220 bp fragment,
which demonstrates the presence of the antisense RNA, was
evident only in the amplified products from the liver RNA of a
transgenic animal (lane b). No fragment could be seen when liver
RNA from normal mice was tested (lane a) or when the reverse
transcription reaction was omitted before amplification of RNA
from a transgenic mouse (lane c). In addition, Figure 2A shows
the 820 bp product obtained after amplification of genomic DNA
from a transgenic mouse (lane d). The product size is augmented
by the 600 bp of the intron sequences.
The RT-PCR method was then used to determine the tissue-
specific expression of the antisense gene. RNA samples from
different tissues were submitted to analysis and the results are
presented in Figure 2B. No transgene expression could be ob-
served in tissues from a normal mouse. In contrast, high liver
expression was manifest in the transgenic mouse. In addition,
significant expression could be seen in the brain of transgenic
animals. Finally, the result of the amplification of the mouse
/3-actin mRNA from the different tissue is presented in Figure 2C,
demonstrating the presence of RNA in each sample.
Levels of angiotensinogen message in transgenic animals
The liver, the brain and the kidney have been described as
containing significant amount of angiotensinogen mRNA. Since
the antisense gene appeared to be expressed in detectable amount
in the liver and in the brain of transgenic animals, the effect on the
endogenous angiotensinogen message was investigated in these
tissues. We also tested the effect on the angiotensinogen mRNA
concentrations in the kidney since, in some experiments, a faint
expression of the transgene was detected in this tissue (data not
shown), and also because the pepck promoter was previously
reported to direct the expression in the kidney [21]. Figure 3
shows the levels of angiotensinogen message detected by quanti-
tative RNAse protection assay in the liver, brain and kidney of
either normal or transgenic mice. In accordance to previously
published observations, the amounts of mRNA in the kidney and
in the brain of normal animals were approximately a fifth of those
observed in the liver. Surprisingly, the amount of angiotensinogen
message in the liver of transgenic mice was not significantly
diminished but was even increased as compared to normal
animals. A similar result was observed in the brain whereas the
kidney showed a slight decrease in the mRNA concentrations
(Figs. 3 and 4).
Levels of angiotensinogen mRNA in mice fed a high protein diet
Since the pepck promoter is responsive to diet, the animals
were fed a regimen devoid of carbohydrate (high protein diet) for
different times and the amounts of angiotensinogen mRNA in
tissues were determined (Fig. 4). The first striking observation was
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a marked increase in the levels of the liver angiotensinogen
mRNA in normal mice kept on a high protein diet as compared to
normal animals fed a normal chow. This increased amount of
message in the liver seemed constant during the entire course of
the experiment. In contrast, the effect of the antisense expression
in transgenic animals appeared to blunt the angiotensinogen
mRNA accumulation during the first twenty days. However, the
level of message in the liver gradually increased to reach values
observed in normal animals around thirty days after starting the
diet. The situation in the kidney very much reflected that seen in
the liver. On the contrary, the high protein diet did not seem to
induce any reduction of the levels of angiotensinogen message in
the brain.
Plasma angiotensinogen concentrations in normal vs. transgenic
adult mice
Plasma angiotensinogen concentrations were also determined
in normal and transgenic mice (Fig. 5). As expected from the
amounts of mRNA found in the liver, the angiotensinogen plasma
levels were significantly higher in transgenic animals as compared
to normal mice. Then, normal and transgenic mice were kept for
different times on high protein diet before measuring angio-
tensinogen concentrations. Similarly to what was seen at the
mRNA level, a high protein diet gradually increased angio-
tensinogen concentrations in the plasma of normal animals.
Angiotensinogen accumulation peaked 80 days after starting the
diet. In contrast, the regimen in transgenic mice led to a slight
reduction in plasma angiotensinogen levels. Although modest,
this decrease was significant after thirty days on a high protein diet
(P < 0.005).
Plasma angiotensinogen concentrations in normal versus
transgenic newborn mice
The compensation that operates in transgenic animals seems to
take place over a period of several weeks. We therefore postulate
that a sudden switch from no expression to high expression of the
antisense transgene should facilitate the demonstration of the
antisense inhibition. As already mentioned, the pepck gene pro-
moter is not active during the fetal life but the expression reaches
its maximum just after birth. We decided then to measure the
plasma angiotensinogen concentrations in either normal or trans-
genic newborn animals. Immediately after birth, normal mice
showed a strong rise in their plasma angiotensinogen levels (Fig.
6). A gradual reduction was then observed and plasma angio-
tensinogen values approached those measured in adult animals.
In transgenic animals, this peak was very much reduced as the
result of the antisense expression. However, the difference in
plasma angiotensinogen concentrations between control and
transgenic animals progressively diminished, and the values mea-
sured in transgenic mice even exceeded normal levels by day 5
after birth. Thereafter, the difference between the values of the
transgenic versus the normal group was similar to that observed in
adult animals.
Blood pressure and heart rate in normal versus transgenic mice
Blood pressure and heart rate were also examined in normal
and transgenic mice and the results of a representative experiment
are depicted in Figure 7. No difference in these two parameters
could be observed between the two groups of animals. Short or
long period of a high protein diet were ineffective in changing
these parameters in transgenic animals (data not shown).
Discussion
In this report, we describe a transgenic mouse line that carries
an antisense angiotensinogen gene. Transient inhibition of angio-
tensinogen mRNA accumulation in tissues was demonstrated in
this model. In addition, significant reduction of the levels of
plasma angiotensinogen protein was also observed in transgenic
animals in which the expression of the transgene was suddenly
activated. However, a long-term blockade of the renin-angioten-
sin system appears difficult using this approach.
The antisense gene used in this study is composed of the rat
pepck gene promoter coupled to a full-length rat angiotensinogen
cDNA. The species difference does not represent a major obstacle
since the mouse and the rat sequences share long stretches of
complete homology, with an overall identity of more than 90%
[25, 27, 28], and more importantly, because this combination was
successfully used to inhibit angiotensinogen production by hepa-
toma cells that were stably transfected with an antisense angio-
tensinogen gene [15]. In transgenic animals, the fragment of the
pepck promoter has been shown to direct the expression of
different protein to liver and kidney tissues [21]. In the present
work, the antisense angiotensinogen transgene expression was
detected in the liver, the brain and possibly the kidney. Expression
in the central nervous system under the control of the pepck
promoter was not reported previously. It is possible that, depend-
ing on the site of transgene integration in the mouse genome,
leaky expression could emerge. Although transgene expression
could be readily demonstrated using a PCR assisted technique, we
were not able to detect the presence of the antisense RNA using
the quantitative RNA protection assay. The reason might be that
a competition binding to the antisense RNA takes place between
the endogenous angiotensinogen mRNA and the RNA probe,
both of them being complementary to the antisense molecule,
during the hybridization step of the ribonuclease assay.
The amounts of angiotensinogen mRNA were then determined
in the different tissues that express the transgene. Surprisingly, no
dramatic reduction in the levels of angiotensinogen mRNA was
observed in transgenic mice. In fact, the levels of angiotensinogen
message appeared even increased in the liver of transgenic mice
whereas changes in the brain or in the kidney were marginal (Fig.
3). Although expression of the antisense transgene is barely
detectable in the kidneys, the pepck promoter has been shown to
be active in this tissue [21]. This might explain the small reduction
in the levels of renal angiotensinogen mRNA. The fact that the
brain levels appeared slightly augmented could be a reflection of
the different regulation of the angiotensinogen gene in different
tissue [2]. Correspondingly to what was seen at the mRNA level,
the plasma angiotensinogen was also increased in transgenic
animals fed a normal diet (Fig. 5). The amount of message in the
kidney and in the brain represents approximately 20% of that
found in the liver (Fig. 3) [2, 3]. Moreover, a parallel increase in
the amounts of hepatic angiotensinogen mRNA and the levels of
the plasma protein was observed between normal and transgenic
animals (Figs. 3 and 5). It is therefore unlikely that the kidney or
the brain constituted a significant source that would be responsi-
ble for the increase in the angiotensinogen plasma levels observed
in transgenic animals.
To boost the expression of the antisense transgene, mice were
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fed a high protein diet [21, 22]. This diet also dramatically
increased the amount of endogenous angiotensinogen message in
the liver of normal mice, although it did not change the levels of
angiotensinogen mRNA in the brain or in the kidney as previously
described by others (Fig. 4) [29, 30]. The possible reason for this
liver-specific increase is unknown, but differential regulation of
angiotensinogen production in various tissues has been reported.
For instance, glucocorticoids, estrogens and thyroid hormones
modify differently liver, kidney and brain angiotensinogen mRNA
production [2, 31, 32]. In addition, insulin has been shown to
negatively regulate angiotensinogen expression in liver-derived
cells [33]. On a high protein diet, the levels of circulating insulin
are dramatically reduced. It is therefore possible that the absence
of this potentially negative signal resulted in an increased tran-
scription of the angiotensinogen gene.
The apparent discrepancy between the level of reduction
observed in the angiotensinogen message and that seen in plasma
protein in transgenic animals could reflect decreased steady-state
levels of angiotensinogen message in the face of an increased
mRNA turnover in response to the antisense inhibition. Alterna-
tively, one cannot exclude the possibility that different tissues
could contribute to the plasma angiotensinogen concentrations
upon antisense activation. However, it is unlikely that the kidney
would play a major role since a reduction of angiotensinogen
message similar to that seen in the liver, was observed in this
tissue (Fig. 4). The amounts of brain angiotensinogen mRNA on
the other hand did not appear to be significantly diminished by the
expression of the antisense transgene, even when the animals were
placed on a high protein diet. On the contrary, the levels of brain
message seemed slightly augmented compared to control.
Whether or not this difference could explain the 20% rise in
plasma levels remain to be elucidated. Other tissues have been
described to transcribe the angiotensinogen gene. However, the
presence of angiotensinogen message in the heart, the lung or the
spleen was not detected (data not shown). Finally, a high protein
diet has been shown to activate plasma renin activity [34, 35],
which in turn could increase circulating concentrations of angio-
tensin II. This peptide is thought to increase angiotensinogen
gene transcription and to therefore participate in a feedback
mechanism that restores angiotensinogen plasma levels [36—38].
The antisense inhibition was further documented in newborn
animals in which a sudden switch from no activity of the pepck
promoter (and therefore of transgene transcription) to maximum
activity naturally occurs immediately after birth [22]. The study of
the antisense effect appeared also facilitated by the rise in the
amount of liver angiotensinogen message as well as in the plasma
angiotensinogen concentrations that occur during the first post-
natal days [39—41]. This enhanced angiotensinogen expression is
probably secondary to an increase in plasma steroid and thyroid
hormones, which are known to rise after birth and stimulate
angiotensinogen gene transcription [2]. A clear decrease of the
angiotensinogen plasma levels was then observed in two- to
four-day-old transgenic mice compared to normal animals. Again,
the antisense inhibition was overcome by a compensatory phe-
nomenon that was even able to increase plasma concentrations
five days after birth. At that time, the difference between normal
control and transgenic mice was similar to that seen in adult
animals.
Different attempts have been made to partially knock out gene
expression in transfected cells or in transgenic mice with antisense
RNA's. Although the cellular approach has proved to be success-
ful [14, 15], targeted antisense expression in transgenic animals
led to mixed results [161. We were indeed able to show inhibition
of angiotensinogen message and protein synthesis in a transgenic
mouse line that carries an antisense angiotensinogen gene. How-
ever, the antisense inhibitory effect was only transient because a
compensation took place that brought the angiotensinogen mes-
sage and plasma concentrations back to control values. Renin
expression in the kidneys and plasma renin activity are not
different in the two group of mice (data not shown). As a
consequence, it is not surprising that blood pressure and heart
rates do not appear to be modified by the presence of the
transgene (Fig. 7). Finally, the exact molecular mechanisms that
account for the compensatory mechanism remain to be eluci-
dated, but it is of interest that the levels of angiotensinogen
protein in transgenic mice were remarkably stable over time. The
antisense RNA might have introduced an extra level of regulation.
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